Revelation Biosciences Presents Positive Data from Prime Clinical Study

Gemini drug normalizes inflammation and restores immune function in chronic kidney disease patients

Mar. 30, 2026 at 4:01pm

Got story updates? Submit your updates here. ›

Revelation Biosciences, Inc., a clinical-stage biotechnology company, has presented additional positive data from its Prime clinical study, showing that its lead drug candidate Gemini was able to durably normalize cellular inflammation and restore immunocompetence in chronic kidney disease (CKD) patients.

Why it matters

The findings are significant as a majority of CKD patients present with cellular inflammation and immunoparalysis prior to treatment. Restoring immune function is crucial for managing inflammatory diseases, and these results suggest Gemini could be an effective therapy for CKD and other inflammatory conditions.

The details

The data showed that Gemini was able to durably normalize the cellular inflammation and restore immunocompetence in CKD patients who had previously exhibited these issues. This represents an important step forward in the development of treatments for inflammatory diseases.

  • The data was presented on March 30, 2026.

The players

Revelation Biosciences, Inc.

A clinical-stage biotechnology company developing treatments for inflammatory diseases.

Gemini

Revelation Biosciences' lead drug candidate that was shown to normalize inflammation and restore immune function in the Prime clinical study.

Got photos? Submit your photos here. ›

The takeaway

These positive results for Gemini in the treatment of inflammation and immune dysfunction in CKD patients represent an important milestone in the development of new therapies for inflammatory diseases, which often involve complex immune system dysregulation.